

# SECURITIES AND EXCHANGE COMMISSION

## FORM 8-A12B

Form for the registration/listing of a class of securities on a national securities exchange  
pursuant to Section 12(b)

Filing Date: **2022-05-11**  
SEC Accession No. [0001193125-22-147272](#)

([HTML Version](#) on [secdatabase.com](#))

### FILER

#### **Bellevue Life Sciences Acquisition Corp.**

CIK: [1840425](#) | IRS No.: **845052822** | State of Incorporation: **DE** | Fiscal Year End: **1231**  
Type: **8-A12B** | Act: **34** | File No.: [001-41390](#) | Film No.: **22913017**  
SIC: **6770** Blank checks

Mailing Address  
*10900 NE 4TH STREET,  
SUITE 2300  
BELLEVUE WA 98004*

Business Address  
*10900 NE 4TH STREET,  
SUITE 2300  
BELLEVUE WA 98004  
425-635-7700*

---

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-A**

---

**FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES  
PURSUANT TO SECTION 12(b) OR (g) OF  
THE SECURITIES EXCHANGE ACT OF 1934**

---

**BELLEVUE LIFE SCIENCES ACQUISITION CORP.**  
(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction of incorporation or organization)

**84-5052822**  
(I.R.S. Employer Identification No.)

**10900 NE 4th Street**  
**Suite 2300**  
**Bellevue, WA**  
(Address of principal executive offices)

**98004**  
(Zip Code)

**Securities to be registered pursuant to Section 12(b) of the Act:**

<u>to be so registered</u>	<u>Title of each class</u>	<u>each class is to be registered</u>	<u>Name of each exchange on which</u>
Units, each consisting of one share of common stock and one redeemable warrant			The Nasdaq Stock Market LLC
Common stock, par value \$0.0001			The Nasdaq Stock Market LLC
Redeemable warrants, exercisable for shares of common stock at an exercise price of \$11.50 per share			The Nasdaq Stock Market LLC

---

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. ☒

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ☐

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ☐

**Securities Act registration statement or Regulation A offering statement file number to which this form relates:**  
**333-264597 (if applicable)**

**Securities to be registered pursuant to Section 12(g) of the Act:**

**None**  
(Title of Class)

---

---

---

**Item 1. Description of Registrant's Securities to be Registered**

The securities to be registered hereby are the units, common stock and redeemable warrants of Bellevue Life Sciences Acquisition Corp. (the "Registrant"). The description of the units, common stock and warrants contained under the heading "Description of Securities" in the registration statement initially filed with the Securities and Exchange Commission on April 29, 2022 (File No. 333-264597) (as amended from time to time, the "Registration Statement") to which this Form 8-A relates is incorporated herein by reference. Any form of prospectus or prospectus supplement to the Registration Statement that includes such descriptions and that are subsequently filed are hereby also incorporated by reference herein.

**Item 2. Exhibits**

Pursuant to the instructions for Form 8-A, no exhibits are required to be filed, because no other securities of the registrant are registered on The Nasdaq Stock Market LLC, and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

---

SIGNATURE

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereto duly authorized.

**BELLEVUE LIFE SCIENCES ACQUISITION CORP.**

Date: May 11, 2022

By: /s/ Kuk Hyoun Hwang

Kuk Hyoun Hwang

Chief Executive Officer